"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Descriptor ID |
D011960
|
MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1997 | 0 | 2 | 2 |
1999 | 2 | 2 | 4 |
2000 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2003 | 1 | 1 | 2 |
2004 | 2 | 1 | 3 |
2005 | 0 | 1 | 1 |
2006 | 1 | 3 | 4 |
2007 | 1 | 2 | 3 |
2008 | 1 | 0 | 1 |
2009 | 2 | 1 | 3 |
2010 | 2 | 1 | 3 |
2011 | 3 | 5 | 8 |
2012 | 2 | 2 | 4 |
2013 | 0 | 3 | 3 |
2014 | 0 | 1 | 1 |
2015 | 3 | 3 | 6 |
2016 | 4 | 1 | 5 |
2017 | 2 | 2 | 4 |
2018 | 1 | 3 | 4 |
2019 | 0 | 5 | 5 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Sociodemographic disparities in molecular testing for breast cancer. Cancer Causes Control. 2022 Jun; 33(6):843-859.
-
Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021 04 01; 4(4):e216322.
-
BMI, physical activity, and breast cancer subtype in white, black, and Sea Island breast cancer survivors. Adv Cancer Res. 2020; 146:83-102.
-
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019 10; 20(10):1360-1369.
-
Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer. Breast Cancer Res. 2019 07 17; 21(1):80.
-
Oncoplastic Breast Surgery Compared to Conventional Breast-Conserving Surgery With Regard to Oncologic Outcome. Clin Breast Cancer. 2019 12; 19(6):423-432.e5.
-
Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. BMC Cancer. 2019 May 23; 19(1):491.
-
Deletion of Cdkn1b in ACI rats leads to increased proliferation and pregnancy-associated changes in the mammary gland due to perturbed systemic endocrine environment. PLoS Genet. 2019 03; 15(3):e1008002.
-
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. J Cell Physiol. 2019 06; 234(6):7708-7717.
-
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019 Feb; 173(3):559-571.